

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : To Be Assigned
Applicant : Don J. DIAMOND
Filed : October 31, 2003
TC/A.U. : 1648
Examiner : Ali Reza Salimi

Docket No. : 1954-435
Customer No. : 06449
Confirmation No. : To Be Assigned

INFORMATION DISCLOSURE STATEMENT


Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The material listed on the accompanying forms PTO-1449 forms, from the parent application having U.S. Serial Number 10/238,607, is cited in compliance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Applicant respectfully requests that the Examiner consider these references with respect to the present application. Copies of these references can be found with the parent application and, accordingly, will not be resubmitted unless requested by the Examiner.

Respectfully submitted,

By


Martha Cassidy
Attorney for Applicants
Registration No. 44,066
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040

Enclosure(s):
PTO-1449 Forms

1954-435.ids.wpd

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	To Be Assigned
				Filing Date	October 31, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
Examiner Name	Ali Reza Salimi				
Sheet	1	of	7	Attorney Docket Number	1954-435

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A.	6,074,645		Diamond et al.	06/13/00
	B.	5,736,142		Sette et al.	04/07/98
	C.	5,075,213		Pande et al.	12/24/91
	D.	5,405,940		Boon et al.	04/11/95
	E.	5,470,730		Greenberg et al.	11/28/95

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
	F.	WO	99/19349		City of Hope	04/22/99	
	G.	WO	97/40165		The Wistar Institute of Anatomy and Biology	10/30/97	
	H.	WO	00/75180		Anmelder und	12/14/00	
	I.	WO	98/26074		Institut National De La Sante Et De La Recherche Medicale	06/18/98	
	J.	WO	94/00150		City of Hope	01/06/94	
	K.	WO	92/05794		Immunex Corporation	04/16/92	
	L.	WO	96/06929		Fred Hutchinson Cancer Research Center	03/07/96	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	To Be Assigned
				Filing Date	October 31, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
Examiner Name	Ali Reza Salimi				
Sheet	2	of	7	Attorney Docket Number	1954-435

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	M.	Moldoveanu et al., "CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal Immunization with Influenza Virus," <u>Vaccine</u> , 16:11/12:1216-1224, 1998.	
	N.	Alexander et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <u>Immunity</u> 1:751-761, December 1994.	
	O.	Bernhard et al., "Cytotoxic T Lymphocytes from HLA-A2 Transgenic Mice Specific for HLA-A2 Expressed on Human Cells," <u>J. Exp. Med.</u> 168:1157-1162, September 1988.	
	P.	Berzofsky et al., "Construction of peptides Encompassing Multideterminant Clusters of Human Immunodeficiency Virus Envelope to Induce in Vitro T Cell Responses in Mice and Humans of Multiple MHC Types," <u>The J. of Clinical Investigation</u> 88:876-884, September 1991.	
	Q.	Boppana et al., "Recognition of Human Cytomegalovirus Gene Products by HCMV-specific Cytotoxic T Cells," <u>Virology</u> 222:293-296, 1996.	
	R.	Borysiewicz et al., "Relative Frequency of Stage-specific CTL Recognizing the 72-kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses," <u>J. Exp. Med.</u> 168:919-931, September 1988.	
	S.	Brouwenstijn et al., "Definition of Unique and Shared T-Cell Defined Tumor Antigens in Human Renal Cell Carcinoma," <u>J. of Immunotherapy</u> 21(6):427-434, 1998.	
	T.	Chujoh et al., "The role of anchor residues in the binding of peptides to HLA-A*1101 molecules," <u>Tissue Antigens</u> 52:501-509, 1998.	
	U.	Clay et al., "Changes in the Fine Specificity of gp100 ₍₂₀₉₋₂₁₇₎ -Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue," <u>J. of Immunology</u> , 1749-1755, 1999.	
	V.	Greenberg et al. "Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantatoin recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded <i>in vitro</i> " <u>Annals of the New York Academy of Sciences</u> 636:184-195, 1991.	
	W.	Gyulai et al., "Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1-Specific CTLs," <u>The J. of Infectious Diseases</u> 181:1537-46, 2000.	
	X.	Ishioka et al. "Utilization of MHC Class I transgenic mice for development of minigen DNA vaccines encoding multiple HLA-restricted CTL epitopes" <u>J. Immunology</u> 162:3915-3925, 1999.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	To Be Assigned
				Filing Date	October 31, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
Examiner Name	Ali Reza Salimi				
Sheet	3	of	7	Attorney Docket Number	1954-435

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	Y.	Kern et al., "Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides," <u>Eur. J. Immunol.</u> 30:1676-1682, 2000.	
	Z.	Kern et al., "Target Structures of the CD8 ⁺ -T Cell Response to Human Cytomegalovirus: the 72 Kilodalton Major Immediate-Early Protein Revisited," <u>J. of Virology</u> 73(10):8179-8184, Oct. 1999.	
	AA.	Lipford et al. "Peptide Engineering Allows Cytotoxic T-cell Vaccination Against Human jPapilloma Virus Tumour Antigen, E6" <u>Immunology</u> 84:298-303, 1995.	
	BB.	Livingston et al. "Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans" <u>J. Immunology</u> 162:3088-3095, 1999.	
	CC.	Ohlin et al. "Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus" <u>Clin. Exp. Immunol.</u> 84:508-514, 1991.	
	DD.	Oseroff et al. "Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses" <u>Vaccine</u> 16(8):823-833, 1998.	
	EE.	Panina-Bordignon et al., "Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells," <u>Eur. J. Immunol.</u> 19:2237-2242, 1989.	
	FF.	Retière et al., "Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool to Study the Fine Specificity of the Antiviral Response," <u>J. of Virology</u> 74(9):3948-3952, May 2000.	
	GG.	Riddell et al. "Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression" <u>J. Immunology</u> 146(8):2795-2804, April 15, 1991.	
	HH.	Rüger et al. "Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus" <u>J. Virology</u> 61(2):446-453 February 1987.	
	II.	Schild et al., "Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells," <u>Eur. J. Immunol.</u> 21:2649-2654, 1991.	
	JJ.	Theobald et al., "Targeting p53 as a general tumor antigen," <u>Proc. Natl. Acad. Sci. USA</u> 92:11993-11997, December 1995.	
	KK.	Tsunoda et al. "Lipopeptide particles as the immunologically active component of CTL inducing vaccines," <u>Vaccine</u> 17:675-685, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	To Be Assigned
				Filing Date	October 31, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
Examiner Name	Ali Reza Salimi				
Sheet	4	of	7	Attorney Docket Number	1954-435

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	LL.	Vierboom et al. "Peptide Vaccination with an Anchor-Replaced CTL Epitope Protects Against Human Papillomavirus Type 16-Induced Tumors Expressing the Wild-Type Epitope," <u>J. Immunotherapy</u> 219(6):399-408, 1998.	
	MM.	Wentworth et al., "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," <u>Eur. J. Immunol.</u> 26:97-101, 1996.	
	NN.	Wentworth et al. "In Vitro induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," <u>Molecular Immunology</u> 32(9):603-612, 1995.	
	OO.	Quinnan et al., "HLA-Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients," <u>The New England Journal of Medicine</u> 307(1): 7-13, 1982.	
	PP.	Borysiewicz et al., "Human Cytomegalovirus-Specific Cytotoxic T Lymphocytes: Requirements for <i>in vitro</i> Generation and Specificity," <u>Eur. J. Immunol.</u> 13:804-809, 1983.	
	QQ.	Clark et al., "Isolation and Partial Chemical Characterization of a 64,000-Dalton Glycoprotein of Human Cytomegalovirus," <u>Journal of Virology</u> 49(1):279-282, 1984.	
	RR.	Forman et al., "A 64,000 Dalton Matrix Protein of Human Cytomegalovirus Induces In Vitro Immune Responses Similar to Those of Whole Viral Antigen", <u>The Journal of Immunology</u> 134(5):3391-3395, 1985.	
	SS.	Meyers et al., "Risk Factors for Cytomegalovirus Infection After Human Marrow Transplantation," <u>The Journal of Infectious Diseases</u> 153(3):478-488, 1986.	
	TT.	Miller et al., "Retrovirus-Mediated Gene Transfer into Human Skin Fibroblasts", March 1988 Meeting at Cold Spring Harbor.	
	UU.	Borysiewicz et al., "Relative Frequency of Stage-Specific CTL Recognizing the 72-kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses," <u>J. Exp. Med.</u> 168:919-931, 1988.	
	VV.	Miller et al., "Design of Retrovirus Vectors for Transfer and Expression of the Human β -Globin Gene," <u>Journal of Virology</u> 62(11):4337-4345, 1988.	
	WW.	Townsend et al., "Recognition of Influenza Virus Proteins by Cytotoxic T Lymphocytes", <u>Phil. Trans. R. Soc. Lond. B</u> 323:527-533, 1989.	
	XX.	Gelinas et al., "Regulated Expression of the Human β -Globin Gene After Retroviral Transfer into Murine and Human Hematopoietic Cells", <u>Hemoglobin Switching, Part B: Cellular and Molecular Mechanisms</u> , pp. 235-249, 1989.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	To Be Assigned
				Filing Date	October 31, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
Examiner Name	Ali Reza Salimi				
Sheet	5	of	7	Attorney Docket Number	1954-435

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	YY.	Pande et al., "Structural Analysis of a 64-kDa Major Structural Protein of Human Cytomegalovirus (Towne): Identification of a Phosphorylation Site and Comparison to pp65 of HCMV (AD169)", <u>Virology</u> 178:6-14, 1990.	
	ZZ.	Falk et al., "Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted from MHC Molecules," <u>Nature</u> 351:290-296, 1991.	
	AAA.	Schmidt et al., "A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants", <u>The New England Journal of Medicine</u> , 324(15):1005-1011, 1991.	
	BBB.	Del Val et al., "Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein," <u>Cell</u> 68:1145-1153, 1991.	
	CCC.	Penna et al., "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen," <u>J. Exp. Med.</u> 174:1565-1570, 1991.	
	DDD.	Goodrich et al., "Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation," <u>The New England Journal of Medicine</u> 325(23):1601-1607, 1991.	
	EEE.	Reusser et al., "Cytotoxic T-Lymphocyte Response to Cytomegalovirus After Human Allogeneic Bone Marrow Transplantation: Pattern of Recovery and Correlation With Cytomegalovirus Infection and Disease," <u>Blood</u> 78(5):1373-1380, 1981.	
	FFF.	Riddell et al., "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones," <u>Science</u> 257:238-241, 1992.	
	GGG.	Missale et al., "HLA-A31 and HLA-Aw68-Restricted Cytotoxic T Cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope During Acute Viral Hepatitis", <u>J. Exp. Med.</u> 177:751-762, 1993.	
	HHH.	Gilbert et al., "Selective Interference with Class I Major Histocompatibility Complex Presentation of the Major Immediate-Early Protein Following Infection with Human Cytomegalovirus," <u>Journal of Virology</u> 67(6):3461-3469, 1993.	
	III.	Bertoletti et al., "Definition of a Minimal Optimal Cytotoxic T-Cell Epitope within the Hepatitis B Virus Nucleocapsid Protein," <u>Journal of Virology</u> 67(4):2376-2380, 1993.	
	JJJ.	Kast et al., "Human Leukocyte Antigen-A2.1 Restricted Candidate Cytotoxic T Lymphocyte Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins Identified by Using the Processing-Defective Human Cell Line T2," <u>Journal of Immunotherapy</u> 14:115-120, 1993.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	To Be Assigned
				Filing Date	October 31, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
Examiner Name	Ali Reza Salimi				
Sheet	6	of	7	Attorney Docket Number	1954-435

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	KKK.	Goodrich et al., "Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant", <u>Annals of Internal Medicine</u> 118:173-178, 1993.	
	LLL.	Winston et al., "Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients," <u>Annals of Internal Medicine</u> 118:179-184, 1993.	
	MMM.	Riddell et al., "Therapeutic Reconstitution of Human Viral Immunity by Adoptive Transfer of Cytotoxic T Lymphocyte Clones," <u>Current Topics in Microbiology and Immunology</u> 189:9-34, 1994.	
	NNN.	Li et al., "Recovery of HLA-Restricted Cytomegalovirus (CMV)-Specific T-Cell Responses After Allogeneic Bone Marrow Transplant: Correlation with CMV Disease and Effect of Ganciclovir Prophylaxis," <u>Blood</u> 83(7):1971-1979, 1994.	
	OOO.	Johnson et al., "Induction of a Major Histocompatibility Complex Class I-Restricted Cytotoxic T-Lymphocyte Response to a Highly Conserved Region of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120 in Seronegative Humans Immunized with a Candidate HIV-1 Vaccine," <u>Journal of Virology</u> 68(5):3145-3153, 1994.	
	PPP.	Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis," <u>Science</u> 265:391-394, 1994.	
	QQQ.	McLaughlin-Taylor et al., "Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8+ Virus-Specific Cytotoxic T Lymphocytes," <u>Journal of Medical Virology</u> 43:103-110, 1994.	
	RRR.	Vitiello et al., "Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBV Infection," <u>J. Clin. Invest.</u> 95:341-349, 1995.	
	SSS.	Walter et al., "Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor," <u>The New England Journal of Medicine</u> 333(16):1038-1044, 1995.	
	TTT.	Drijfhout et al., "Detailed Motifs for Peptide Binding to HLA-A*0201 Derived from Large Random Sets of Peptides Using a Cellular Binding Assay," <u>Human Immunology</u> 43:1-12, 1995.	
	UUU.	D'Amaro et al., "A Computer Program for Predicting Possible Cytotoxic T Lymphocyte Epitopes Based on HLA Class I Peptide-Binding Motifs," <u>Human Immunology</u> 43:13-18, 1995.	
	VVV.	Rasmussen, "Immune Response to Human Cytomegalovirus Infection," <u>Current Topics in Microbiology and Immunology</u> 154:222-254, 1990.	
	WWW.	Zhou et al., "Association Between Prior Cytomegalovirus Infection and the Risk of Restenosis After Coronary Atherectomy," <u>The New England Journal of Medicine</u> 335(9):624-630, 1996.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	To Be Assigned
				Filing Date	October 31, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
Examiner Name	Ali Reza Salimi				
Sheet	7	of	7	Attorney Docket Number	1954-435

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	XXX.	Moss, "Vaccinia Virus Vectors," <u>Construction of Recombinant Viruses</u> , pp. 345-362.	
	YYY.	Pande et al., "Direct DNA Immunization of Mice with Plasmid DNA Encoding the Tegument Protein pp65 (ppUL83) of Human Cytomegalovirus Induces High Levels of Circulating Antibody to the Encoded Protein," <u>Scand J Infect Dis</u> 99:117-120, 1995.	
	ZZZ.	Khattab, B.A. et al., "Three T-Cell Epitopes Within the C-Terminal 265 Amino Acids of the Matrix Protein pp65 of Human Cytomegalovirus Recognized by Human Lymphocytes," <u>Journal of Medical Virology</u> 52:68-76, 1997.	
	AAAA.	Ogg, G.H. et al., "HLA-peptide tetrameric complexes," <u>Immunology</u> 10:393-396, 1998.	
	BBBB.	Pande, H. et al., "Human Cytomegalovirus Strain Towne pp65 Gene: Nucleotide Sequence and Expression in <i>Escherichia coli</i> ," <u>Virology</u> 182:220-228, 1991.	
	CCCC.	Parker, K. et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <u>Journal of Immunology</u> 152:163-175, 1994.	
	DDDD.	Wills, M.R. et al., "The human CTL response to Cytomegalovirus is dominated by structural protein," <u>J. Virology</u> 70:(11):7569-7579, 1996.	
	EEEE.	Tsunoda T. et al., "Serologically identically HLA B35 alleles which do not cross-present minimal cytotoxic epitopes to CD8+CTL," <u>J. Cell. Biochem. Vol. Suppl.</u> 0(19A):298, 1995.	
	FFFF.	Diamond, D.J. et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <u>Nature</u> 342:561-564, 1989.	
	GGGG.	Deres, E.A.: "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <u>Nature</u> 342:561-564, 1989.	
	HHHH.	Gonczol E. et al., "Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate," <u>Vaccine</u> 13(12):1080-1085, 1995.	
	IIII.	Rammensee et al., <u>Immunogenetics</u> 41(4):178-228, 1995.	
	JJJJ.	Livingston et al., <u>J. Immunol.</u> 159:1383-1392, 1997.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.